Therapies

3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments

25 days ago   |   By Xconomy

Three biotech companies collectively raised $584 million in their initial public offerings last week, continuing a streak of IPOs that has the healthcare sector playing a leading role in the robust level of market activity this summer. Of the three companies, the one with investigational therapies that haven't yet begun being tested in humans raised the most. South San Francisco-based Nkarta collected $252 million, money the preclinical firm plans to use to get its lead allogenic, or “off-the-shelf,” cancer therapy into the clinic by year's end and to advance its earlier programs. The...
Read more ...

 


Search by Tags

   Therapies      Healthcare      Biotech      BioTech      Cancer      Clinical      Europe blog main      Europe top stories      National      National blog main      National top stories      New York blog main      New York top stories      San Diego blog main      San Diego top stories      San Francisco blog main      San Francisco top stories      ALX Oncology      Cancer      CAR-NK      CAR-T      Cell Therapy      Clinical trials      Drug Development      Financing      GenFit      Intercept Pharmaceuticals      Inventiva      IPO      ITeos Therapeutics      Life Sciences      Natural killer cells      Nkarta      Pandion Therapeutics      Poseida Therapeutics      SPAC      Therapeutics Acquisition  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Biogen to Pay Denali $1B to Partner on Parkinson's Drug & Other Neuro Meds

Biogen to Pay Denali $1B to Partner on Parkinson's Drug & Other Neuro Meds

Denali Therapeutics has selected a brain-penetrating Parkinson's disease drug candidate to advance to late-stage testing and Biogen is paying $1 billion to kick off a... Read more ...

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

The FDA on Friday approved a new spinal muscular atrophy drug that patients can take at home. Risdiplam is a liquid medicine intended for daily use that was developed by Roche... Read more ...

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It's the second genetic medicines... Read more ...

Five Question Friday: Jo Tang

Five Question Friday: Jo Tang

Welcome to Five Question Friday! This is the first blog post of a new monthly series, where we will introduce you to the employees of GreenLight. You'll get to know our team... Read more ...

Bio Roundup: A Telehealth Combo, FDA's BCMA OK, Biogen's Bet & More

Bio Roundup: A Telehealth Combo, FDA's BCMA OK, Biogen's Bet & More

The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs... Read more ...

Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare

Moderna, Pfizer Protocols May Make COVID Vaccines Hard to Compare

It will be difficult to compare Moderna, Inc. and Pfizer Inc.'s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said. “Both trials appeared to... Read more ...

“Murder Hornet” Genome Rapidly Assembled by USDA as Part of Real-Time...

“Murder Hornet” Genome Rapidly Assembled by USDA as Part of Real-Time Invasive Species Response Initiative

With a nickname like “murder hornet,” it's no wonder the two-inch long Asian giant hornet has caused a stir amongst those terrified of insect invasions. Various species of... Read more ...

GlaxoSmithKline Multiple Myeloma Drug Earns FDA's First Anti-BCMA Nod

GlaxoSmithKline Multiple Myeloma Drug Earns FDA's First Anti-BCMA Nod

Patients with advanced multiple myeloma have a new treatment option with the FDA's approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on... Read more ...

G1 Vets Launch Arc Therapeutics to Take on New Cancer Target

G1 Vets Launch Arc Therapeutics to Take on New Cancer Target

Three early employees of G1 Therapeutics have launched a new oncology-focused company and raised $6 million to move a preclinical program licensed from their former employer... Read more ...

A Closer Look at Water-Splitting's Solar Fuel Potential

A Closer Look at Water-Splitting's Solar Fuel Potential

Francesca Toma and Johanna Eichhorn developed a special technique using an atomic force microscope at Berkeley Lab's JCAP laboratory to capture images of thin-film bismuth... Read more ...